Revamping Skincare: Abe Yōandō Pharmaceuticals Introduces New Design for NMN Serum

Abe Yōandō Pharmaceuticals, based in Adachi, Tokyo, is taking a bold step forward in the skincare market by announcing a rebranding of their flagship product, the NMN 13 Serum. Starting from July 2026, this well-regarded serum will be renamed as the Yōandō 13 Serum and will feature a completely redesigned packaging, while the formula itself remains unchanged.

Key Changes in Branding

- Product Name: Changing from NMN 13 Serum to Yōandō 13 Serum.
- Design: The bottle and outer packaging will showcase a new design, incorporating advanced graphics that reflect the company’s innovative spirit. The structural design of the bottle will not change.
- Implementation Date: The new branding will start to ship on July 1, 2026.

The new design is inspired by the legacy of the sixth-generation founder who opened a Western-style pharmacy in Toranomon. The sleek, organic curves and advanced dot patterns represent a blend of tradition and innovation, symbolizing the ongoing cycle of health and wellness that the Abe family has championed since their inception.

A Rich Heritage Survives the Test of Time

Founded in 1731 by the first-generation pharmacist Sadetaka Abe, Abe Yōandō Pharmaceuticals has a long-standing history of commitment to human health and well-being, serving the Matsudaira family as their official medical practitioners. The company has weathered historical events such as the Meiji Restoration and the Great Kanto Earthquake, maintaining their mission focused on health.

In 2015, the tenth president, Tomotaka Abe, recognized the potential of NMN (Nicotinamide Mononucleotide), a compound that supports cellular health. He submitted vital safety test data to Japan's Ministry of Health, leading to a revision in regulations on March 31, 2020, which officially recognized NMN as a food ingredient. This pivotal change allowed Abe Yōandō Pharmaceuticals to launch NMN supplements, setting them ahead in the market.

Now, the company is in the spotlight, having progressed to the semifinals of the global longevity science competition, XPRIZE Healthspan, placing them at the forefront of anti-aging technologies. The Yōandō 13 Serum is a culmination of their extensive research into NMN, combining liposomal NMN with three types of human stem cell culture solutions and seven functional peptides. The formulation will stay intact with this rebranding.

Product Specifications

- Product Name: Yōandō 13 Serum (formerly NMN 13 Serum)
- Type: Serum
- Price: ¥12,540 (including tax)
- Volume: 30mL
- Release Date: Available starting from July 1, 2026.
- Retailer: Official online shop of Abe Yōandō Pharmaceuticals

Future Developments

Currently, the Yōandō 13 Serum is the sole skincare offering from Abe Yōandō Pharmaceuticals. However, the company has ambitious plans for the future and anticipates launching additional skincare products, including lotions and emulsions, later this summer. The aim is to support health and beauty amidst the growing trend of longevity, ensuring that the benefits of their innovative research are accessible to a broader audience.

About Abe Yōandō Pharmaceuticals

Since its founding nearly 300 years ago, Abe Yōandō Pharmaceuticals has blended Eastern medicinal wisdom with Western medical insights to pursue health and longevity. They continue to develop unique research that combines traditional health practices with cutting-edge longevity science.

Company Information:

- Headquarters: 1-5-4 YAK Kitasenju Building, Yanagihara, Adachi-ku, Tokyo 120-0022
- Ginza Office: 6-3-12 Sukiya Building, 6th floor, Ginza, Chuo-ku, Tokyo 104-0061
- Founded: 1731
- Established: December 1984
- CEO: Tomotaka Abe
- Website: Abe Yōandō Pharmaceuticals